Back to Search
GOTTFRIED KONECNY, MD
MD
Hematology & Oncology Physician
NPI: 1427190115IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
A124261(CA)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A124261(CA)
Education
OTHER
Class of 1989
Research & Publications (20)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
PMID 16452222·Cancer Res·2006
7-preclinical
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
PMID 15685824·Oncology (Williston Park)·2004
6-review
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
PMID 15292386·J Natl Cancer Inst·2004
8-other
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
PMID 15014023·Clin Cancer Res·2004
8-other
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
PMID 12529347·J Natl Cancer Inst·2003
8-other
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
PMID 11561768·Breast Cancer Res Treat·2001
8-other
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
PMID 11489825·Clin Cancer Res·2001
8-other
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
PMID 11410515·Clin Cancer Res·2001
8-other
Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
PMID 10785475·Gynecol Oncol·2000
8-other
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
PMID 19364964·J Clin Oncol·2009
3-trial
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.
PMID 19088718·Br J Cancer·2009
8-other
A new ELISA for use in a 3-ELISA system to assess concentrations of VEGF splice variants and VEGF(110) in ovarian cancer tumors.
PMID 18310147·Clin Chem·2008
8-other
Rationale for folate receptor alpha targeted therapy in "high risk" endometrial carcinomas.
PMID 18646191·Int J Cancer·2008
8-other
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
PMID 18334972·Br J Cancer·2008
8-other
Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer.
PMID 18313739·Gynecol Oncol·2008
8-other
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
PMID 16403812·Ann Oncol·2006
8-other
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
PMID 15952915·Expert Opin Biol Ther·2005
8-other
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
PMID 15150302·J Natl Cancer Inst·2004
7-preclinical
Chemosensitivity testing in gynecologic oncology--dream or reality?
PMID 12528806·Recent Results Cancer Res·2003
6-review
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
PMID 14679144·J Natl Cancer Inst·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 UCLA MEDICAL PLZ STE 550
LOS ANGELES, CA 90024 - Phone
- (310) 206-1214
Quick Facts
- NPI
- 1427190115
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile